Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07082738 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
1,160
Enrollment target
20
Study locations

NCT07082738 is a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,160 participants, above the 619-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (87% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07082738, a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
1,160 participants
Enrollment target
20
Study locations

Study Summary

This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.

Conditions Studied

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • OTHER Placebo
  • DRUG AZD6793

Study Locations (20)

Florida

  • Research Site - Brandon
  • Research Site - Cape Coral
  • Research Site - Clearwater
  • Research Site - Clearwater
  • Research Site - Jacksonville
  • Research Site - Lake City
  • Research Site - Miami
  • Research Site - Miami

California

  • Research Site - Canoga Park
  • Research Site - La Mesa
  • Research Site - Los Angeles
  • Research Site - Newport Beach
  • Research Site - Norco
  • Research Site - Tustin

Arizona

  • Research Site - Glendale
  • Research Site - Phoenix
  • Research Site - Phoenix
  • Research Site - Phoenix

Alabama

  • Research Site - Birmingham

Colorado

  • Research Site - Lakewood

Trial Details

FieldValue
Enrollment Target 1,160 participants
Start Date 2025-06-27
Est. Completion 2027-11-05
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07082738

The ClinicalTrials.gov registry entry for NCT07082738 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,160 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 619-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (87% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07082738 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT07082738 about?

NCT07082738 is a clinical study titled "A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease". This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.

What is the current status of trial NCT07082738?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,160 participants. The study started on 2025-06-27. Estimated completion is 2027-11-05.

What conditions does trial NCT07082738 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).

What interventions are being tested in trial NCT07082738?

The interventions under investigation include: Placebo (OTHER), AZD6793 (DRUG).

Who is sponsoring clinical trial NCT07082738?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07082738 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Obstructive Pulmonary Disease (COPD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Obstructive Pulmonary Disease (COPD)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.